To test if blocking KLRG1 engagement with this neutralizing antibody has any effect on the anti-tumor activity of T cells in the MMTV-PyMT model, we treated 12-week WT MMTV-PyMT mice with either isotype control or anti-KLRG1 antibody once every 3 days for three weeks. Here, KLRG1 is linked to neoplasm.